PE20060274A1 - (4-metoxi-7-morfolin-4-il-benzotiazol-2-il)amida del acido 4-hidroxi-4-metil-piperidin-1-carboxilico - Google Patents

(4-metoxi-7-morfolin-4-il-benzotiazol-2-il)amida del acido 4-hidroxi-4-metil-piperidin-1-carboxilico

Info

Publication number
PE20060274A1
PE20060274A1 PE2005000569A PE2005000569A PE20060274A1 PE 20060274 A1 PE20060274 A1 PE 20060274A1 PE 2005000569 A PE2005000569 A PE 2005000569A PE 2005000569 A PE2005000569 A PE 2005000569A PE 20060274 A1 PE20060274 A1 PE 20060274A1
Authority
PE
Peru
Prior art keywords
benzothiazol
morpholin
methoxy
hydroxy
methyl
Prior art date
Application number
PE2005000569A
Other languages
English (en)
Inventor
Alexander Flohr
Jean-Luc Moreau
Sonia Maria Poli
Lucinda Steward
Claus Riemer
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34967309&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20060274(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20060274A1 publication Critical patent/PE20060274A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

SE REFIERE A (4-METOXI-7-MORFOLIN-4-IL-BENZOTIAZOL-2-IL)AMIDA DEL ACIDO 4-HIDROXI-4-METIL-PIPERIDIN-1-CARBOXILICO, SALES ACIDAS DE ADICION FARMACEUTICAMENTE ACEPTABLES. SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE PREPARACION QUE COMPRENDE REACCIONAR 4-METOXI-7-MORFOLIN-4-IL-BENZOTIAZOL-2-IL-AMINA CON 4-HIDROXI-4-METIL-1-CLOROCARBONIL-PIPERIDINA. DICHOS COMPUESTOS SON ANTAGONISTAS DEL RECEPTOR A2A DE ADENOSINA UTILES EN EL TRATAMIENTO DE ALZHEIMER, PARKINSON, HUMTINGTON, ESQUIZOFRENIA, ANSIEDAD, ENTRE OTROS
PE2005000569A 2004-05-24 2005-05-23 (4-metoxi-7-morfolin-4-il-benzotiazol-2-il)amida del acido 4-hidroxi-4-metil-piperidin-1-carboxilico PE20060274A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04102262 2004-05-24

Publications (1)

Publication Number Publication Date
PE20060274A1 true PE20060274A1 (es) 2006-04-14

Family

ID=34967309

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000569A PE20060274A1 (es) 2004-05-24 2005-05-23 (4-metoxi-7-morfolin-4-il-benzotiazol-2-il)amida del acido 4-hidroxi-4-metil-piperidin-1-carboxilico

Country Status (39)

Country Link
US (1) US7368446B2 (es)
EP (1) EP1753760B1 (es)
JP (1) JP4668265B2 (es)
CN (1) CN1956983B (es)
AR (1) AR048973A1 (es)
AT (1) ATE382619T1 (es)
AU (1) AU2005247567B2 (es)
BR (1) BRPI0511543B1 (es)
CA (1) CA2567703C (es)
CR (1) CR8703A (es)
CY (1) CY1108104T1 (es)
DE (1) DE602005004142T2 (es)
DK (1) DK1753760T3 (es)
DO (1) DOP2005000091A (es)
EA (1) EA011279B1 (es)
EC (1) ECSP067018A (es)
ES (1) ES2297710T3 (es)
GT (1) GT200500124A (es)
HK (1) HK1105199A1 (es)
HN (1) HN2005000238A (es)
HR (1) HRP20080027T3 (es)
IL (1) IL179364A (es)
MA (1) MA28601B1 (es)
MX (1) MXPA06013417A (es)
MY (1) MY140011A (es)
NO (1) NO336939B1 (es)
NZ (1) NZ550763A (es)
PA (1) PA8633901A1 (es)
PE (1) PE20060274A1 (es)
PL (1) PL1753760T3 (es)
PT (1) PT1753760E (es)
RS (1) RS50574B (es)
SI (1) SI1753760T1 (es)
SV (1) SV2006002125A (es)
TN (1) TNSN06371A1 (es)
TW (1) TWI358297B (es)
UA (1) UA87142C2 (es)
WO (1) WO2005116026A1 (es)
ZA (1) ZA200609136B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE521512C2 (sv) * 2001-06-25 2003-11-11 Niconovum Ab Anordning för administrering av en substans till främre delen av en individs munhåla
DE60313216T2 (de) * 2002-12-20 2008-01-03 Niconovum Ab Chemisch und physikalisch stabiles teilchenförmiges material enthaltend nikotin und microcrystalline cellulose
JP5694645B2 (ja) 2006-03-16 2015-04-01 ニコノヴァム エービーＮｉｃｏｎｏｖｕｍ Ａｂ 改善された嗅ぎたばこ組成物
AU2008279169A1 (en) * 2007-07-23 2009-01-29 Biotie Therapies, Inc 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide for the treatment of post-traumatic stress disorder
PL2385938T3 (pl) 2009-01-12 2015-07-31 Pfizer Ltd Pochodne sulfonamidu
US8168785B2 (en) * 2009-06-17 2012-05-01 Biotie Therapies, Inc. Benzothiazole derivatives
WO2011101861A1 (en) 2010-01-29 2011-08-25 Msn Laboratories Limited Process for preparation of dpp-iv inhibitors
ES2532356T3 (es) 2010-07-09 2015-03-26 Pfizer Limited N-sulfonilbenzamidas como inhibidores de los canales de sodio dependientes de voltaje
WO2012060844A1 (en) * 2010-11-05 2012-05-10 Biotie Therapies, Inc A2a antagonists as cognition and motor function enhancers
KR20140146217A (ko) * 2012-04-20 2014-12-24 유씨비 파마, 에스.에이. 파킨슨병을 치료하는 방법
JP2018517785A (ja) * 2015-06-19 2018-07-05 バイオティー セラピーズ インコーポレイテッド 制御放出トザデナント製剤
WO2018059531A1 (zh) * 2016-09-30 2018-04-05 苏州晶云药物科技有限公司 一种腺苷a2a受体拮抗剂药物的晶型及其制备方法和用途
AU2018320672B2 (en) * 2017-08-21 2023-09-07 Merck Patent Gmbh Quinoxaline derivatives as adenosine receptor antagonists
CN110997662B (zh) * 2017-08-21 2023-10-31 默克专利股份公司 作为腺苷受体拮抗剂的苯并咪唑衍生物
WO2019141096A1 (zh) * 2018-01-19 2019-07-25 四川科伦博泰生物医药股份有限公司 取代脲类化合物及其制备方法和用途
JP2022515741A (ja) 2018-12-20 2022-02-22 バイオティー セラピーズ インコーポレイテッド トザデナントを使用して癌を処置する方法
DE102019110904B4 (de) 2019-04-26 2022-01-20 Helmholtz-Zentrum Dresden - Rossendorf E. V. N-(4-methoxy-7-morpholinobenzo[d]thiazol-2-yl)-acetamid-Derivate und deren Verwendung

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH505543A (de) 1968-11-01 1971-04-15 Ciba Geigy Ag Schädlingsbekämpfungsmittel
NL7109150A (es) 1970-07-06 1972-01-10
US4028374A (en) * 1975-11-03 1977-06-07 Morton-Norwich Products, Inc. Antibacterial thiocyanatobenzothiazoles
DE2656468A1 (de) 1976-12-14 1978-06-15 Boehringer Mannheim Gmbh N-(benzthiazol-2-yl)-oxamidsaeure- derivate und verfahren zu ihrer herstellung
KR930005004B1 (ko) 1985-04-15 1993-06-11 쟈안센 파아마슈우티카 엔. 부이. 치환된 n-[(4-피페리디닐)알킬]이환 축합 옥사졸아민 및 티아졸아민의 제조방법
FI91859C (fi) 1987-06-17 1994-08-25 Eisai Co Ltd Analogiamenetelmä antiallergisena aineena aktiivisen bentsotiatsolijohdannaisen valmistamiseksi
IL90337A0 (en) 1988-05-24 1989-12-15 Pfizer Aromatic and heterocyclic carboxamide derivatives as antineoplastic agents
WO1990015801A1 (en) 1989-06-22 1990-12-27 Pfizer Inc. Substituted sulfonamides and related compounds in the treatment of asthma, arthritis and related diseases
EP0427963B1 (de) 1989-11-10 1994-03-30 Agrolinz Agrarchemikalien Gesellschaft M.B.H. Verfahren zur Herstellung reiner, unsymmetrisch disubstituierter Harnstoffe
ATE188704T1 (de) 1992-05-21 2000-01-15 Otsuka Pharma Co Ltd Phosphonsäurediester-derivat
FR2753970B1 (fr) 1996-10-01 1998-10-30 Synthelabo Derives de n-(benzothiazol-2-yl) piperidine-1-ethanamine, leur preparation et leur application en therapeutique
JPH11130761A (ja) 1997-10-24 1999-05-18 Otsuka Pharmaceut Co Ltd ベンゾチアゾール誘導体
NZ503491A (en) 1997-11-10 2002-08-28 Bristol Myers Squibb Co 2-substituted amino-1,3-benzothiazole derivatives useful as protein tyrosine kinase inhibitors
KR20010015910A (ko) 1998-01-23 2001-02-26 로렌스 티. 마이젠헬더 옥사졸리디논 조합 라이브러리, 조성물 및 제조 방법
EP1117663A2 (en) 1998-09-30 2001-07-25 Neurogen Corporation 2-piperazino alkylamino benzoazole derivatives: dopamine receptor subtype specific ligands
GB9824579D0 (en) * 1998-11-10 1999-01-06 Novartis Ag Organic compounds
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
IL133680A0 (en) 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
DE60023949T2 (de) 2000-05-12 2006-08-10 Corning Inc. Verfahren zum herstellen einer vorform mit schutzumhüllung für optische fasern
MXPA02012596A (es) * 2000-06-21 2003-04-10 Hoffmann La Roche Derivados de benzotiazol.
US6727247B2 (en) * 2001-12-10 2004-04-27 Hoffman-La Roche Inc. Substituted benzothiazole amide derivatives
US6713499B2 (en) * 2001-12-12 2004-03-30 Hoffman-La Roche Inc. 7-Amino-benzothiazole derivatives

Also Published As

Publication number Publication date
WO2005116026A1 (en) 2005-12-08
HRP20080027T3 (en) 2008-05-31
NO20065732L (no) 2006-12-22
AR048973A1 (es) 2006-06-14
EA011279B1 (ru) 2009-02-27
CA2567703C (en) 2013-03-05
DK1753760T3 (da) 2008-04-14
NO336939B1 (no) 2015-11-30
TW200612937A (en) 2006-05-01
DOP2005000091A (es) 2005-06-29
EP1753760A1 (en) 2007-02-21
JP2008500295A (ja) 2008-01-10
US20050261289A1 (en) 2005-11-24
CA2567703A1 (en) 2005-12-08
MA28601B1 (fr) 2007-05-02
AU2005247567A1 (en) 2005-12-08
JP4668265B2 (ja) 2011-04-13
PT1753760E (pt) 2008-02-12
AU2005247567B2 (en) 2010-09-02
CY1108104T1 (el) 2014-02-12
MXPA06013417A (es) 2007-01-23
SI1753760T1 (sl) 2008-04-30
EA200602048A1 (ru) 2007-06-29
PL1753760T3 (pl) 2008-06-30
IL179364A (en) 2013-01-31
RS50574B (sr) 2010-05-07
SV2006002125A (es) 2006-02-15
IL179364A0 (en) 2007-03-08
CR8703A (es) 2007-10-04
NZ550763A (en) 2010-07-30
ECSP067018A (es) 2006-12-29
CN1956983A (zh) 2007-05-02
DE602005004142D1 (de) 2008-02-14
BRPI0511543A (pt) 2008-01-02
BRPI0511543B1 (pt) 2022-05-10
ZA200609136B (en) 2008-07-30
ES2297710T3 (es) 2008-05-01
US7368446B2 (en) 2008-05-06
ATE382619T1 (de) 2008-01-15
PA8633901A1 (es) 2006-05-16
MY140011A (en) 2009-11-30
GT200500124A (es) 2005-12-26
HN2005000238A (es) 2008-07-14
EP1753760B1 (en) 2008-01-02
DE602005004142T2 (de) 2009-01-02
UA87142C2 (en) 2009-06-25
TWI358297B (en) 2012-02-21
TNSN06371A1 (fr) 2008-02-22
HK1105199A1 (en) 2008-02-06
CN1956983B (zh) 2010-05-26

Similar Documents

Publication Publication Date Title
PE20060274A1 (es) (4-metoxi-7-morfolin-4-il-benzotiazol-2-il)amida del acido 4-hidroxi-4-metil-piperidin-1-carboxilico
UY35572A (es) Nuevos agonistas del receptor de somatostatina subtipo 4 (sstr4)
CY1120258T1 (el) Ενωσεις ετεροδικυκλο-υποκατεστημενης-[1,2,4]τριαζολο [1,5-c]κιναζολιν-5-αμινης καταλληλες για αγωγη ή προληψη διαταραχων του κεντρικου νευρικου συστηματος
CL2011001263A1 (es) Compuestos derivados de pirimidinonas opcionalmente sustituidas; composicion farmaceutica que los comprende; y su uso como inhibidores de fosfodiesterasa 1 (pde1) para el tratamiento de enfermedades que involucran trastornos de la trayectoria intracelular del receptor de dopamina d1 como parkinson, alzheimer, depresion, enfermedad bipolar, hipertension, glaucoma.
DOP2013000267A (es) Hidroximetil pirrolidinas como agonistas del receptor adrenérgico beta 3
CO6440524A2 (es) Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de la quinasa janus.
CY1116892T1 (el) Ενωσεις οι οποιες εχουν δραστικοτητα ανταγωνιστη μουσκαρινικου υποδοχεα και αγωνιστη βητα2 αδρενεργικου υποδοχεα
CL2012001366A1 (es) Compuestos derivados de carboxamida n-((2-morfolino-5-ariltiazol-4-il)metil), moduladores de receptores nicotinicos alfa 7; composicion farmaceutica; proceso para prepararla; combinacion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer, demencia, esquizofrenia, enfermedad de parkinson, entre otras.
UY32574A (es) Antagonistas del receptor cxcr3
PE20230156A1 (es) Sal de acido clorhidrico de (r)-4-(3-((s)-1-(4-amino-3-metil-1h pirazolo[3,4-d]pirimidin-1-il)etil)-5-cloro-2-etoxi-6-fluorofenil)pirrolidin-2-ona
TW200740814A (en) Compounds
PE20181492A1 (es) Compuestos sustituidos de 4-fenilpiridina como agonistas de tgr5 no sistemicos
CR8711A (es) Indazoles, benzotiazoles, benzoisotiazoles, benzisoxazoles y preparacion y usos de estos
AR072557A1 (es) Proceso para preparar composiciones de medicamentos que contienen dabigatran
PE20151001A1 (es) Alcoxipirazoles como activadores de guanilato ciclasa soluble
UY32629A (es) Compuestos antivirales, composiciones y uso para la manufactura de un medicamento para el tratamiento de trastornos asociados con hepatitis c.
UY32923A (es) Compuestos policíclicos como antagonistas del receptor de ácido lisofosfatídico
CR10682A (es) Compuestos de tiazol pirazolopirimidina
AR061727A1 (es) Sintesis de dietil [[ 5- ( 3-fluorofenil) -piridin -2il] metil] fosfonato
PE20180116A1 (es) HETEROCICLILMETIL-TIENOURACILO COMO AGONISTAS DEL RECEPTOR DE ADENOSINA A2b
UY29212A1 (es) Azabenzoxazoles para el tratamiento de trastornos del snc
CR8786A (es) Procesos para preparacion de antagonistas de receptor de hormona que libera gonadotropina
GT200900007A (es) Derivados de purina como agonistas de a2a
NI201000023A (es) Derivados de indol-2-ona disustituidos en 3, su preparación y su aplicación en terapéutica.
CY1113820T1 (el) Παραγωγα 4-αλκοξυπυριδαζινης ως ταχεως διασπομενοι ανταγωνιστες υποδοχεα ντοπαμινης 2

Legal Events

Date Code Title Description
FG Grant, registration